Journal: Brain, behavior, and immunity

Article Title: HIV-1 Tat protein enhances sensitization to methamphetamine by affecting dopaminergic function

doi: 10.1016/j.bbi.2017.05.004

Figure Lengend Snippet: Immunohistochemistry on paraffin embedded sections was utilized examine the protein distribution and levels of dopamine receptor D1 (A, B, C, D), dopamine receptor D2 (E, F, G, H), as well as of IBA-1 (I, J, K, L) in SAL TAT− (A, E, I), SAL TAT+ (B, F, J), METH TAT− (C, G, K), and METH TAT+ (D, H, L) mice. Representative positive cells in the 40× magnification images were labeled with a black arrow. (M) Normalized intensity density was calculated in ImageJ. Data are expressed as Mean ± SEM (n=5). * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: Sections were blocked with 5g/l Casein (Sigma Aldrich) in PBS, containing 0.5g/l Thimerosal (Sigma Aldrich) and incubated with Iba-1 antibody (Wako Lab Chemicals, Richmond, VA), the anti-mouse DRD1 antibody (NLS43, Novus Biologicals, Littleton, CO), or anti mouse DRD2 (orb154598, Biorbyt, San Francisco, CA), each one diluted in Casein buffer.

Techniques: Immunohistochemistry, Labeling

Journal: bioRxiv

Article Title: Neuronal glutamate transporters control dopaminergic signaling and compulsive behaviors

doi: 10.1101/224477

Figure Lengend Snippet: (A) Western blots for D1R, D2R and ß-actin in WT (n=ll) and EAAC1 −/− mice (n=8) show decreased levels of D1R (***p=2.7e-4), not D2R (p=0.51), in EAAC1 −/− mice. (B) Western blot analysis for DARPP-32, showing no significant difference in its expression between WT (n=15) and EAAC1 −/− mice (n=12, p=0.92). (C) Western blot analysis for pDARPP-32 T34 (WT (n=10), EAAC1 −/− (n=10), p=0.41), pDARPP-32 175 (WT (n=13), EAAC1 −/− (n=14), p=0.84), pDARPP-32 S97 (WT (n=13), EAAC1 −/− (n=13), p=0.98), pDARPP-32 S130 (WT (n=14), EAAC1 −/− (n=17), *p=0.024). (D) Pie chart representation of the phosphorylation distribution on the T34, T75, S97 and S130 sites of DARPP-32. The red curve highlights the S130 site, which shows increased phosphorylation in EAAC1 −/− mice. (E) As in (C), following data normalization by the average band intensity values measured in WT mice (pDARPP-32 T34 WT (n=10), EAAC1 −/− (n=10), p=0.46; pDARPP-32 T75 WT (n=13), EAAC1 −/− (n=14), p=0.72; pDARPP-32 S97 WT (n=13), EAAC1 −/− (n=13), p=0.89; pDARPP-32 5130 WT (n=14), EAAC1 −/− (n=15), **p=2.1e-3). Data in panels ?,?,? represent the band intensity ratio between the target protein and β-actin in samples from WT versus EAAC1 7 ' mice in the same blotting membrane.

Article Snippet: We used the following primary antibodies: rabbit anti D1R and D2R (1:200, Cat# ADR-001 and ADR-002 respectively; Alomone Labs, Jerusalem, Israel); rabbit anti mGluR5/1a (1:500, Cat# 2032-mGluR5/1a; PhosphoSolutions, Aurora, CO); rabbit anti GLAST (1:1,000, Cat# 5684; Cell Signaling Technology, Danvers, MA); rabbit anti GLT-1 (1:1,000, Cat# 3838; Cell Signaling Technology, Danvers, MA); rabbit anti DARPP-32 (1:1,000, Cat# 2306; Cell Signaling Technology, Danvers, MA); rabbit antibodies against different pDARPP-32 isoforms (pDARPP-32 T34 , 1:500, Cat# 12438; Cell Signaling Technology, Danvers, MA), (pDARPP-32 T75 and pDARPP-32 S97 , 1:1,000, Cat# 2301 and Cat# 3401 respectively; Cell Signaling Technology, Danvers, MA), (pDARPP-32 S130 , 1:500, Cat# p1025-137; PhosphoSolutions, Aurora, CO), mCherry (Cat# 600-401-P16 Rockland Antibodies & Assays, Limerick, PA) and β-actin (1:1,000, Cat# 4970, Cell Signaling Technology, Danvers, MA).

Techniques: Western Blot, Expressing

Journal: bioRxiv

Article Title: Neuronal glutamate transporters control dopaminergic signaling and compulsive behaviors

doi: 10.1101/224477

Figure Lengend Snippet: (A) Western blots for D1R, D2R and β-actin, in the presence of the mGluRI blockers LY367385 (50 μM) and MPEP (10 μM), show no significant difference in the expression of D1R and D2R (D1R: WT (n=9), EAAC1 −/− (n=9), p=0.35; D2R: WT (n=7), EAAC1 −/− (n=7), p=0.064). (B) mGluRI blockade induces a slight reduction in DARPP-32 expression between WT (n=9) and EAAC1 −/− mice (n=9, *p=0.029). (C) Western blot analysis for pDARPP-32 T34 (WT (n=5), EAAC1 −/− (n=6), p=0.98), pDARPP-32 T75 (WT (n=6), EAAC1 −/− (n=7), *p=0.017), pDARPP-32 S97 (WT (n=9), EAAC1 −/− (n=9), p=0.34), pDARPP-32 S130 (WT (n=12), EAAC1 −/− (n=9), **p=4.6e-3). (D) Pie chart representation of the phosphorylation distribution on the T34, T75, S97 and S130 sites of DARPP-32 in the presence of mGluRI blockers. The red curves highlight the T75 and S130 site, which show reduced phosphorylation in EAAC1 −/− mice. (E) As in (C), following data normalization by the average band intensity values measured in WT mice (WT (n=5), EAAC1 −/− (n=6), p=0.62), pDARPP-32 T75 (WT (n=9), EAAC1 −/− (n=7), ***p=1.0e-5), pDARPP-32 S97 (WT (n=9), EAAC1 −/− (n=9), p=0.16), pDARPP-32 S130 (WT (n=12), EAAC1 −/− (n=9), ***p=2.1e-4). Data in panels A,B,E represent the band intensity ratio between the target protein and β-actin measured in samples from EAAC1 −/− mice and normalized by analogous measures in samples from WT mice blotted in the same membrane.

Article Snippet: We used the following primary antibodies: rabbit anti D1R and D2R (1:200, Cat# ADR-001 and ADR-002 respectively; Alomone Labs, Jerusalem, Israel); rabbit anti mGluR5/1a (1:500, Cat# 2032-mGluR5/1a; PhosphoSolutions, Aurora, CO); rabbit anti GLAST (1:1,000, Cat# 5684; Cell Signaling Technology, Danvers, MA); rabbit anti GLT-1 (1:1,000, Cat# 3838; Cell Signaling Technology, Danvers, MA); rabbit anti DARPP-32 (1:1,000, Cat# 2306; Cell Signaling Technology, Danvers, MA); rabbit antibodies against different pDARPP-32 isoforms (pDARPP-32 T34 , 1:500, Cat# 12438; Cell Signaling Technology, Danvers, MA), (pDARPP-32 T75 and pDARPP-32 S97 , 1:1,000, Cat# 2301 and Cat# 3401 respectively; Cell Signaling Technology, Danvers, MA), (pDARPP-32 S130 , 1:500, Cat# p1025-137; PhosphoSolutions, Aurora, CO), mCherry (Cat# 600-401-P16 Rockland Antibodies & Assays, Limerick, PA) and β-actin (1:1,000, Cat# 4970, Cell Signaling Technology, Danvers, MA).

Techniques: Western Blot, Expressing

Journal: bioRxiv

Article Title: Neuronal glutamate transporters control dopaminergic signaling and compulsive behaviors

doi: 10.1101/224477

Figure Lengend Snippet: (A) Timeline of the experimental design. At P14-16, mice received a unilateral stereotaxic injection of hM3D(Gq). After one week, they started receiving daily I/P saline injections. At P28-30, they received I/P injections of CNO (5 mg/Kg). One hour after the CNO injections, they were video-monitored to examine their grooming behavior. Two hours after the CNO injections, they were sacrificed. Proteins for Western blot analysis were extracted from the control and injected striatum and from the adjacent cortices. (B) Left: mCherry expression in D1 Cre/+ mice. A significant increase in mCherry expression was detected only in the striatum of D1 Cre/+ mice (n=10, *p=0.040). Right: mCherry expression in A2A Cre/+ mice. A significant increase in mCherry expression was detected only in the striatum of A2A Cre/+ mice (n=23, *p=0.035). (C) Left: D1R and D2R expression in D1 Cre/+ mice (D1R: n=9, *p=0.013; D2R: n=8, p=0.35). The expression of D1R is significantly reduced in the injected striatum. Right: D1R and D2R expression in A2A Cre/+ mice (D1R: n=9, p=0.63; D2R: n=5, p=0.34). The expression of D1R and D2R is similar in the injected and non-injected striatum. (D) Left: hM3D(Gq) injection in D1 Cre/+ mice leads to increased pDARPP-32 S130 (pDARPP-32 T34 n=10, p=0.92; pDARPP-32 T75 n=11, p=0.18; pDARPP-32 S97 n=11, p=0.13, pDARPP-32 S130 n=11, **p=5.6e-3). Right: hM3D(Gq) injection in A2A Cre/+ mice leads to no change in pDARPP-32 (pDARPP-32 T34 n=9, p=0.75; pDARPP-32 T75 n=8, p=0.84; pDARPP-32 S97 n=8, p=0.31, pDARPP-32 S130 n=6, p=0.89). (E) Summary of the frequency (Frequency: Sham (n=25), D1 Cre/+ (n=39), Sham vs D1 Cre/+ **p=6.0e-3, A2A Cre/+ (n=49), Sham vs A2A Cre/+ p=0.28) and duration of grooming episodes in Sham and D1 Cre/+ mice injected with hM3D(Gq) (Duration: Sham (n=34), D1 Cre/+ (n=44), Sham vs D1 Cre/+ p=0.12, A2A Cre/+ (n=58), Sham vs A2A Cre/+ p=0.08). (F) Relationship between the frequency and duration of grooming episodes in Sham (left), D1 Cre/+ (middle) and A2A Cre/+ mice (right). The inset represents a density plot of the data, with blue areas corresponding to the duration and frequency of the most commonly observed grooming episodes.

Article Snippet: We used the following primary antibodies: rabbit anti D1R and D2R (1:200, Cat# ADR-001 and ADR-002 respectively; Alomone Labs, Jerusalem, Israel); rabbit anti mGluR5/1a (1:500, Cat# 2032-mGluR5/1a; PhosphoSolutions, Aurora, CO); rabbit anti GLAST (1:1,000, Cat# 5684; Cell Signaling Technology, Danvers, MA); rabbit anti GLT-1 (1:1,000, Cat# 3838; Cell Signaling Technology, Danvers, MA); rabbit anti DARPP-32 (1:1,000, Cat# 2306; Cell Signaling Technology, Danvers, MA); rabbit antibodies against different pDARPP-32 isoforms (pDARPP-32 T34 , 1:500, Cat# 12438; Cell Signaling Technology, Danvers, MA), (pDARPP-32 T75 and pDARPP-32 S97 , 1:1,000, Cat# 2301 and Cat# 3401 respectively; Cell Signaling Technology, Danvers, MA), (pDARPP-32 S130 , 1:500, Cat# p1025-137; PhosphoSolutions, Aurora, CO), mCherry (Cat# 600-401-P16 Rockland Antibodies & Assays, Limerick, PA) and β-actin (1:1,000, Cat# 4970, Cell Signaling Technology, Danvers, MA).

Techniques: Injection, Western Blot, Expressing

Journal: bioRxiv

Article Title: Cell-Type Specific Profiling of Histone Post-Translational Modifications in the Adult Mouse Striatum

doi: 10.1101/2022.01.17.476614

Figure Lengend Snippet: A) Immunohistochemistry displaying DAPI/GFP/A2A (left) and D1 (right) from the striatum of SUN1-GFP;A2a-CRE+ animals. Arrows indicate co-localization of all three markers. B) Immunohistochemistry displaying DAPI/GFP/DRD1 (left) and A2A (right) from the striatum of SUN1-GFP; D1-CRE+ animals. Arrows indicate co-localization of all three markers. C) INTACT schematic created at Biorender.com. D) Purity (&) of Cre+ cells in STR. Image depicts total nuclei isolation. E) Yield (&) and Purity (&) of GFP+ nuclei. Image depicts GFP+ nuclei isolation. F) mRNA validation for INTACT Sun1-GFP; A2a-Cre+ vs bulk (Cre-nuclei) G) mRNA validation for INTACT Sun1-GFP;D1-Cre + vs bulk (Cre-nuclei) (right).

Article Snippet: Sections were blocked for 90 minutes at room temperature with 10& Normal Donkey Serum and 0.2& Triton X-100 in PBS and then incubated with 0.2& Triton X-100 in PBS with the following antibodies overnight at 4°C: rabbit anti-Drd1 (1:500, Bioss USA BSM-52920R) or rabbit anti-A2a (1:200, Fisher Scientific PA1-042), co-incubated with goat anti-GFP (1:500, Rockland, 600-101-215).

Techniques: Immunohistochemistry, Isolation

Journal: bioRxiv

Article Title: Cell-Type Specific Profiling of Histone Post-Translational Modifications in the Adult Mouse Striatum

doi: 10.1101/2022.01.17.476614

Figure Lengend Snippet: A-C) A2a and D1 specific H3K4me3 and H3K27me3 modifications around known cell-type markers A2a (A) , Drd1 (B) , and Camk2a (C) . D ) A2a H3K4me3 signal, ( E) A2a H3K27me3 signal, (F) D1 H3K4me3 signal, (G) and D1 H3K27me3 signal centered on transcription start site (TSS). For each cell-type and hPTM, genes are categorized into 3 groups: high (FPKM >= 10), medium (1 <= FPKM < 10), and low (FPKM < 1) based on published MSN-specific Ribo-Tag . Signal is normalized to total mapped reads: Count Per Million (CPM).

Article Snippet: Sections were blocked for 90 minutes at room temperature with 10& Normal Donkey Serum and 0.2& Triton X-100 in PBS and then incubated with 0.2& Triton X-100 in PBS with the following antibodies overnight at 4°C: rabbit anti-Drd1 (1:500, Bioss USA BSM-52920R) or rabbit anti-A2a (1:200, Fisher Scientific PA1-042), co-incubated with goat anti-GFP (1:500, Rockland, 600-101-215).

Techniques:

Journal: Nutrition Research and Practice

Article Title: Dopamine and serotonin alterations by Hizikia fusiformis extracts under in vitro cortical primary neuronal cell cultures

doi: 10.4162/nrp.2023.17.3.408

Figure Lengend Snippet: HF, Hizikia fusiformis extract treatment; VEH, vehicle treatment (control); DRD1-5, dopamine D1–5 receptors; DAT, dopamine transporter; DAPI, 4′,6-diamidino-2-phenylindole; NF-L, neurofilament light chain; SERT, serotonin transporter; TH, tyrosine hydroxylase; TPH, tryptophan hydroxylase; SYP, synaptophysin; 5HT1A and 1B, serotonin 1A and 1B receptors; MAP2, microtubule-associated protein 2.

Article Snippet: In this study, we used primary antibodies for DA transmission: mouse monoclonal anti-tyrosine hydroxylase (TH; Abcam; catalog #ab129991), rabbit polyclonal anti-DAT (Santa Cruz; catalog #sc-14002), rabbit polyclonal anti-dopamine receptor D1 (DRD1; Santa Cruz; catalog #sc-14001), mouse monoclonal anti-DRD2 (Santa Cruz; catalog #sc-5303), mouse monoclonal anti-DRD3 (Santa Cruz; catalog #sc-136170), rabbit polyclonal anti-DRD4 (Elabscience; catalog #E-AB-31153), and rabbit polyclonal anti-DRD5 (Mybiosource; catalog #MBS2516950) antibodies; those for 5-HT transmission: rabbit polyclonal anti-5HT1A (Elabscience; catalog #E-AB-32950), rabbit polyclonal anti-5HT1B (Abcam; catalog #ab13896), anti-tryptophan hydroxylase (TPH; catalog #E-AB-16937), and mouse monoclonal anti-SERT (Santa Cruz; catalog #sc-33724) antibodies; and those for neuronal structures: mouse monoclonal anti-synaptophysin (SYP; Sigma-Aldrich; catalog #S5768), mouse monoclonal anti-microtubule-associated protein 2 (MAP2; Santa Cruz; catalog #sc-32791), and mouse monoclonal neurofilament-light chain (NF-L; Santa Cruz; catalog #sc-20012) antibodies.

Techniques:

Journal: Nutrition Research and Practice

Article Title: Dopamine and serotonin alterations by Hizikia fusiformis extracts under in vitro cortical primary neuronal cell cultures

doi: 10.4162/nrp.2023.17.3.408

Figure Lengend Snippet: DRD1–5, dopamine D1–5 receptors; HF, Hizikia fusiformis extract treatment; VEH, vehicle treatment (control); DAT, dopamine transporter; TH, tyrosine hydroxylase.

Article Snippet: In this study, we used primary antibodies for DA transmission: mouse monoclonal anti-tyrosine hydroxylase (TH; Abcam; catalog #ab129991), rabbit polyclonal anti-DAT (Santa Cruz; catalog #sc-14002), rabbit polyclonal anti-dopamine receptor D1 (DRD1; Santa Cruz; catalog #sc-14001), mouse monoclonal anti-DRD2 (Santa Cruz; catalog #sc-5303), mouse monoclonal anti-DRD3 (Santa Cruz; catalog #sc-136170), rabbit polyclonal anti-DRD4 (Elabscience; catalog #E-AB-31153), and rabbit polyclonal anti-DRD5 (Mybiosource; catalog #MBS2516950) antibodies; those for 5-HT transmission: rabbit polyclonal anti-5HT1A (Elabscience; catalog #E-AB-32950), rabbit polyclonal anti-5HT1B (Abcam; catalog #ab13896), anti-tryptophan hydroxylase (TPH; catalog #E-AB-16937), and mouse monoclonal anti-SERT (Santa Cruz; catalog #sc-33724) antibodies; and those for neuronal structures: mouse monoclonal anti-synaptophysin (SYP; Sigma-Aldrich; catalog #S5768), mouse monoclonal anti-microtubule-associated protein 2 (MAP2; Santa Cruz; catalog #sc-32791), and mouse monoclonal neurofilament-light chain (NF-L; Santa Cruz; catalog #sc-20012) antibodies.

Techniques:

Journal: Nutrition Research and Practice

Article Title: Dopamine and serotonin alterations by Hizikia fusiformis extracts under in vitro cortical primary neuronal cell cultures

doi: 10.4162/nrp.2023.17.3.408

Figure Lengend Snippet: A summary of BF 10 with post-hoc pair wise comparisons

Article Snippet: In this study, we used primary antibodies for DA transmission: mouse monoclonal anti-tyrosine hydroxylase (TH; Abcam; catalog #ab129991), rabbit polyclonal anti-DAT (Santa Cruz; catalog #sc-14002), rabbit polyclonal anti-dopamine receptor D1 (DRD1; Santa Cruz; catalog #sc-14001), mouse monoclonal anti-DRD2 (Santa Cruz; catalog #sc-5303), mouse monoclonal anti-DRD3 (Santa Cruz; catalog #sc-136170), rabbit polyclonal anti-DRD4 (Elabscience; catalog #E-AB-31153), and rabbit polyclonal anti-DRD5 (Mybiosource; catalog #MBS2516950) antibodies; those for 5-HT transmission: rabbit polyclonal anti-5HT1A (Elabscience; catalog #E-AB-32950), rabbit polyclonal anti-5HT1B (Abcam; catalog #ab13896), anti-tryptophan hydroxylase (TPH; catalog #E-AB-16937), and mouse monoclonal anti-SERT (Santa Cruz; catalog #sc-33724) antibodies; and those for neuronal structures: mouse monoclonal anti-synaptophysin (SYP; Sigma-Aldrich; catalog #S5768), mouse monoclonal anti-microtubule-associated protein 2 (MAP2; Santa Cruz; catalog #sc-32791), and mouse monoclonal neurofilament-light chain (NF-L; Santa Cruz; catalog #sc-20012) antibodies.

Techniques:

Journal: International Journal of Molecular Sciences

Article Title: Alteration of the Dopamine Receptors’ Expression in the Cerebellum of the Lysosomal Acid Phosphatase 2 Mutant (Naked–Ataxia ( NAX )) Mouse

doi: 10.3390/ijms21082914

Figure Lengend Snippet: RNA sequencing data analysis in nax ( n = 5) and wild–type (wt) ( n = 6) mice. Data analysis shows dopamine receptor D1 ( Drd1, A ), Drd3 ( C ), and Drd4 ( D ) are significantly increased in the nax cerebellum. Although an increase in Drd2 ( B ) and Drd5 ( E ) is apparent, statistical significance was not reached. The data in the bar graph are presented as the mean ± SEM, and statistical analysis was performed using an unpaired t –test (* p < 0.05 and ** p < 0.01). RPKM: Reads Per Kilobase of transcript per Million mapped reads.

Article Snippet: D1: rabbit polyclonal anti–D1 dopamine receptor (TA328798, anti–Drd1, diluted 1:1000; OriGene Biotech Co., Rockville, MD, USA); D2: rabbit polyclonal anti–D2 dopamine receptor (TA328800, anti–Drd2, diluted 1:1000; OriGene Biotech Co., Rockville, MD, USA), produced against recombinant rat dopamine receptor 2 (DR2); D3: rabbit polyclonal anti–D3 dopamine receptor (TA328800, anti–Drd3, diluted 1:1000; OriGene Biotech Co., Rockville, MD, USA), produced against recombinant rat dopamine receptor 3 (DR3); D4: rabbit polyclonal anti–D4 dopamine receptor (TA321202, anti–DRD4, diluted 1:1000; OriGene Biotech Co., Rockville, MD, USA), produced against recombinant rat dopamine receptor D4 (DRD4); and D5: rabbit polyclonal anti–D5 dopamine receptor (TA328802, anti–Drd5, diluted 1:1000; OriGene Biotech Co., Rockville, MD, USA), produced against recombinant rat dopamine receptor 5 (DR5).

Techniques: RNA Sequencing Assay

Journal: International Journal of Molecular Sciences

Article Title: Alteration of the Dopamine Receptors’ Expression in the Cerebellum of the Lysosomal Acid Phosphatase 2 Mutant (Naked–Ataxia ( NAX )) Mouse

doi: 10.3390/ijms21082914

Figure Lengend Snippet: Frontal sections of wt and nax mouse cerebella: DRD1 expression at P5 and P17. ( A ) Immunoperoxidase staining for DRD1 in the wt cerebellum on P5 shows the immunoreactivity in the Purkinje cell layer (Pcl) and white matter (wm) but not in the external germinal zone (egz) and granular layer (gl). ( B ) Immunoperoxidase staining for DRD1 in the nax cerebellum shows similar immunoreactivity as in the wt littermates at P5. ( C ) DRD1 immunostaining of the frontal sections of the wt cerebellum at P17 shows immunoreactivity in the Purkinje cell (PC) somata, the Pcl, and dendrites in the molecular layer (ml) and in the gl but not in the wm. ( D ) DRD1 immunostaining of the frontal sections of the nax cerebellum on P17 shows immunoreactivity in the PCs in the ml/Pcl. ( E ) Western blot analysis of whole cerebellar lysates revealed no significant differences in DRD1 expression between wt and nax cerebella at P5 and P17 (wt: n = 3 and nax : n = 3). The data in the bar graphs are presented as the means of three independent experiments ± SEM, and statistical analysis was performed using a two–way ANOVA. P; postnatal. Scale bars: 100 μm in A, B, C, and D.

Article Snippet: D1: rabbit polyclonal anti–D1 dopamine receptor (TA328798, anti–Drd1, diluted 1:1000; OriGene Biotech Co., Rockville, MD, USA); D2: rabbit polyclonal anti–D2 dopamine receptor (TA328800, anti–Drd2, diluted 1:1000; OriGene Biotech Co., Rockville, MD, USA), produced against recombinant rat dopamine receptor 2 (DR2); D3: rabbit polyclonal anti–D3 dopamine receptor (TA328800, anti–Drd3, diluted 1:1000; OriGene Biotech Co., Rockville, MD, USA), produced against recombinant rat dopamine receptor 3 (DR3); D4: rabbit polyclonal anti–D4 dopamine receptor (TA321202, anti–DRD4, diluted 1:1000; OriGene Biotech Co., Rockville, MD, USA), produced against recombinant rat dopamine receptor D4 (DRD4); and D5: rabbit polyclonal anti–D5 dopamine receptor (TA328802, anti–Drd5, diluted 1:1000; OriGene Biotech Co., Rockville, MD, USA), produced against recombinant rat dopamine receptor 5 (DR5).

Techniques: Expressing, Immunoperoxidase Staining, Immunostaining, Western Blot